List of Excipients in Branded Drug EMPAVELI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Apellis Pharmaceuticals Inc	EMPAVELI	pegcetacoplan	73606-010	ACETIC ACID	2033-11-15
Apellis Pharmaceuticals Inc	EMPAVELI	pegcetacoplan	73606-010	SODIUM ACETATE	2033-11-15
Apellis Pharmaceuticals Inc	EMPAVELI	pegcetacoplan	73606-010	SODIUM HYDROXIDE	2033-11-15
Apellis Pharmaceuticals Inc	EMPAVELI	pegcetacoplan	73606-010	SORBITOL	2033-11-15
Apellis Pharmaceuticals Inc	EMPAVELI	pegcetacoplan	73606-010	WATER	2033-11-15

EMPAVELI Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Empaveli (pegcetacoplan) is a high-value opportunity for excipient suppliers, formulation developers, container-closure manufacturers, infusion-device companies, and specialty-pharmacy partners. The product’s commercial constraints are driven less by conventional small-molecule solubility than by the stability, viscosity, aggregation, adsorption, and delivery requirements of a pegylated peptide administered by subcutaneous infusion.

The primary opportunity is not a direct copy of the marketed formulation. It is a differentiated delivery platform that can reduce administration burden, improve room-temperature handling, support higher concentration or smaller injection volumes, and preserve biological activity in a complex peptide-polymer conjugate.

What is Empaveli and how is it administered?

Empaveli is a sterile, preservative-free subcutaneous solution containing pegcetacoplan, a pegylated synthetic peptide that inhibits complement component 3, or C3. Apellis Pharmaceuticals developed the product for complement-mediated diseases.

Attribute	Empaveli
Active ingredient	Pegcetacoplan
Pharmacology	C3 inhibitor
FDA dosage form	Sterile injectable solution
Route	Subcutaneous infusion
Marketed strength	54 mg/mL
Commercial presentation	1,080 mg in 20 mL vial
Initial U.S. approval	May 14, 2021
Initial indication	Paroxysmal nocturnal hemoglobinuria
Later U.S. indication	C3 glomerulopathy
Administration	Infusion by an infusion pump, generally over approximately 30 minutes
Key formulation attribute	Preservative-free aqueous formulation

The recommended adult PNH dose is 1,080 mg subcutaneously twice weekly. The C3G regimen uses a weight-based schedule in some patients, which increases the importance of dose flexibility, device compatibility, and administration convenience.[1,2]

What excipients are used in Empaveli?

Empaveli uses a relatively simple aqueous excipient system. The FDA prescribing information identifies glacial acetic acid, sodium chloride, sodium hydroxide for pH adjustment, and water for injection as inactive ingredients.[1]

Excipient or component	Likely formulation function
Water for injection	Aqueous vehicle
Sodium chloride	Tonicity adjustment
Glacial acetic acid	Acid component of the pH-control system
Sodium hydroxide	pH adjustment
Pegcetacoplan	Active pegylated peptide

The formulation does not rely on a conventional preservative, surfactant, sugar stabilizer, or amino-acid excipient in the publicly disclosed label composition. That simplicity can reduce excipient-related regulatory burden, but it places greater pressure on the active molecule, container system, manufacturing process, and cold-chain controls.

The label states that Empaveli is stored refrigerated at 2°C to 8°C and protected from light. The product can be kept at room temperature for a limited period before use, subject to the approved labeling conditions.[1]

What formulation problems must an Empaveli excipient strategy solve?

An Empaveli follow-on formulation must manage six technical risks.

Peptide aggregation

Pegcetacoplan contains a biologically active peptide linked to polyethylene glycol. Peptide aggregation can be promoted by temperature excursions, agitation, repeated handling, freeze-thaw exposure, and contact with air-liquid interfaces.

A formulation developer would normally evaluate:

• Soluble and subvisible particle formation
• High-molecular-weight species
• Loss of complement-binding activity
• Turbidity and color change
• Agitation sensitivity
• Freeze-thaw stability
• In-use stability after vial puncture

Surface adsorption

The active may adsorb to glass, elastomer, tubing, syringe components, and infusion-pump reservoirs. Adsorption can cause dose loss and may increase particle formation.

Potential countermeasures include low-binding polymeric contact materials, carefully selected silicone levels, surface-treated containers, and low-concentration nonionic surfactants. Any surfactant addition would require compatibility testing because the marketed formulation does not disclose one.

Viscosity and injection force

The commercial dose is large: 1,080 mg in a 20 mL vial. The formulation is delivered by subcutaneous infusion rather than a conventional small-volume autoinjector. Higher concentrations could reduce infusion time or total volume, but may increase viscosity and pump pressure.

This creates a direct tradeoff:

Formulation objective	Commercial benefit	Technical risk
Higher concentration	Smaller dose volume	Higher viscosity, aggregation, injection force
Lower viscosity	Easier delivery	May require greater volume
Surfactant addition	Lower interfacial stress	New safety and compatibility burden
Sugar or polyol addition	Potential stabilization	Osmolality and injection tolerability
Buffer expansion	Better pH control	New degradation pathways or package interaction

pH and ionic strength

The disclosed formulation uses an acetic-acid-based pH system and sodium chloride. A replacement buffer could improve stability, but changing ionic strength or pH may alter peptide conformation, PEG behavior, viscosity, and biological potency.

Potential screening candidates include acetate, histidine, phosphate, citrate, and low-capacity mixed buffers. Each carries different risks:

• Phosphate can create precipitation or temperature-dependent pH shifts.
• Citrate can affect metal-sensitive degradation pathways and injection tolerability.
• Histidine may alter peptide stability and oxidation behavior.
• Acetate may provide a simpler regulatory bridge because the marketed product already uses an acetic-acid system.

Container-closure compatibility

Empaveli is a sterile vial product. A commercial reformulation would need extractables and leachables studies covering the vial, stopper, seal, needle, transfer device, tubing, and pump reservoir.

High-priority variables include:

• Silicone oil exposure
• Stopper formulation
• Tungsten residues from vial manufacturing
• Protein or peptide adsorption
• Particulate generation
• Headspace oxygen
• Light transmission
• Vial-puncture performance

Microbiological control

The marketed product is preservative-free. A multi-dose presentation could reduce waste and improve convenience, but a preservative would introduce new local-tolerability, compatibility, and regulatory issues.

For a subcutaneous biologic or peptide product, a preservative-free multi-dose system using a validated sterile cartridge, closed transfer device, or single-use cassette may be commercially more attractive than adding a chemical preservative.

What excipient opportunities exist for Empaveli?

The strongest opportunities are enabling technologies rather than commodity excipients.

Stabilizing surfactant systems

A low-level nonionic surfactant may reduce adsorption and agitation-induced aggregation. Candidate classes include polysorbates, poloxamers, and newer low-peroxide surfactant systems.

The commercial value would come from demonstrating one or more of the following:

• Lower subvisible particle formation
• Longer room-temperature stability
• Better compatibility with infusion tubing
• Improved recovery from primary containers
• Reduced potency loss after transport stress

A surfactant cannot be assumed to improve the product. Oxidation, hydrolysis, peroxide impurities, and interaction with the PEG-peptide conjugate would require a full stability package.

Low-binding delivery systems

Low-binding syringes, tubing, cartridges, and pump reservoirs could produce a measurable dose-recovery advantage without changing the active formulation. This is attractive because it may avoid a major clinical reformulation program.

Commercial products could include:

• Low-adsorption infusion tubing
• Prefilled cartridges
• Closed vial-transfer systems
• Single-use pump cassettes
• Silicone-reduced syringes
• Polymer containers with validated peptide recovery

Higher-concentration formulations

A concentrated formulation could support shorter infusion times or smaller dose volumes. The technical target would be a formulation that maintains acceptable viscosity and biological activity at concentrations above the marketed 54 mg/mL strength.

The principal development path would involve:

1. Concentration screening.
2. Viscosity and pump-pressure testing.
3. Aggregation and particle characterization.
4. Local-tolerability testing.
5. Device compatibility.
6. Human-factor validation.
7. Bridging clinical studies.

This opportunity is commercially significant because the current twice-weekly administration schedule creates a persistent adherence and convenience burden.

Excipient-enabled room-temperature stability

Improved room-temperature stability could reduce cold-chain costs and support specialty-pharmacy distribution. The opportunity is strongest if a formulation can extend the labeled room-temperature window without increasing degradation or particulate formation.

Possible approaches include:

• Optimized buffer capacity
• Low-peroxide surfactants
• Sugar or polyol stabilization
• Oxygen-control packaging
• Light-protective containers
• Improved stopper and vial systems

A longer room-temperature period would have direct value for patients who travel, home-infusion providers, specialty pharmacies, and distributors.

Preservative-free multi-dose systems

A multi-dose presentation could reduce unused drug from twice-weekly administration. The product currently uses a single-dose vial presentation, so a validated multi-dose system could improve inventory efficiency and reduce preparation steps.

Commercial alternatives include:

• A cartridge for a wearable pump
• A sealed multi-dose vial with a closed-access system
• A prefilled syringe or dual-chamber device
• A pump reservoir designed for several days of dosing

The primary risks are microbial ingress, dose accuracy, extractables and leachables, and regulatory classification of the device combination.

What formulations could compete with the marketed Empaveli product?

A competitive development program would likely pursue one of four formulation profiles.

Product concept	Primary value proposition	Main barrier
Higher-concentration aqueous solution	Shorter infusion and lower volume	Viscosity and aggregation
Room-temperature-stable solution	Lower distribution and handling burden	Long-term stability
Prefilled or cartridge-based product	Less preparation and lower dosing error	Device and combination-product development
Multi-dose preservative-free system	Lower waste and improved convenience	Sterility assurance and container compatibility

A dry powder or lyophilized Empaveli product is technically possible but commercially less attractive. Reconstitution would add preparation steps and may undermine the convenience objective unless it materially improves stability or logistics.

What patents protect Empaveli and its formulation?

Empaveli is a biologic product approved under a BLA, not a conventional small-molecule drug approved under an NDA. Its protection is therefore distributed across composition, peptide sequence, PEG conjugation, manufacturing, formulation, and use patents rather than an Orange Book listing alone.

The relevant patent categories are:

• Compstatin and compstatin-analog composition patents
• Pegylated peptide composition patents
• C3-inhibition method-of-treatment patents
• PNH treatment patents
• C3G treatment patents
• Formulation and stability patents
• Conjugation and manufacturing-process patents
• Device and administration patents

The FDA does not list biologic patents for Empaveli in the Orange Book. Biologic patent and exclusivity analysis instead requires review of the Purple Book, FDA approval records, USPTO records, and Apellis patent-family disclosures.[3,4]

When does Empaveli lose exclusivity?

Empaveli received U.S. approval on May 14, 2021. The reference-product exclusivity period for a biological product is generally 12 years from first licensure, subject to statutory limitations and any pediatric extension. On that basis, the principal U.S. reference-product exclusivity date is approximately May 14, 2033.[5]

Empaveli also received orphan-drug protection for PNH. Orphan exclusivity generally lasts seven years from approval of the protected indication, placing the initial PNH orphan period approximately in May 2028.[6]

The later C3G approval may carry separate indication-specific protection, depending on the FDA exclusivity determination and the clinical data supporting the supplemental application. Patent expiration dates may extend beyond regulatory exclusivity and could remain the principal barrier to interchangeable or competing products.

Are Paragraph IV challenges relevant to Empaveli?

A conventional Paragraph IV filing is not the standard pathway for a biologic approved under a BLA. Generic-drug applicants use abbreviated new drug applications and Orange Book certifications. Biosimilar applicants use the Biologics Price Competition and Innovation Act pathway.

A competitor seeking approval for a pegcetacoplan biosimilar would face:

• Reference-product exclusivity
• Biosimilarity and interchangeability requirements
• Analytical comparability of a PEG-peptide conjugate
• Immunogenicity assessment
• Manufacturing-process comparability
• Patent litigation under the BPCIA framework
• Potential device and administration differences

The practical risk is therefore biosimilar entry, not an ordinary Paragraph IV generic launch. A 505(b)(2) or hybrid pathway would require careful analysis of the product’s regulatory classification and could face substantial clinical and patent barriers.

How strong is the Empaveli patent estate?

The estate is likely stronger in composition and manufacturing than in conventional excipient claims.

Stronger protection areas

Composition claims covering the active peptide, PEG architecture, and conjugation configuration can be difficult to design around if the same pharmacologic mechanism and molecular structure are required.

Manufacturing claims may also create barriers because PEG-peptide conjugation can involve complex purification, control of molecular-weight distribution, and characterization of active and inactive species.

More vulnerable protection areas

Formulation claims may be more exposed to design-around strategies. A competitor could potentially use a different buffer, stabilizer, container, concentration, or device while maintaining the same active ingredient.

Method-of-use protection will depend on the scope and enforceability of claims covering PNH, C3G, dosing schedules, and patient subpopulations.

Excipient-specific patent risk

An excipient supplier should conduct a claim chart covering:

• Buffer composition
• Tonicity agent concentration
• Surfactant identity and level
• Concentrated formulation ranges
• Room-temperature storage
• Container and tubing materials
• Pump delivery
• Multi-dose presentations
• Method-of-use claims linked to the formulation

The absence of an Orange Book listing does not mean the formulation is unpatented. It means the patent-dispute analysis must be conducted through BPCIA and general patent records rather than Orange Book certification practice.

What FDA regulatory strategy applies to an Empaveli reformulation?

A reformulated pegcetacoplan product would generally require a biologics license application strategy rather than an ANDA. The pathway depends on whether the developer owns the reference product, licenses relevant rights, or seeks biosimilar status.

Potential regulatory routes include:

Strategy	Likely use
Supplemental BLA	Apellis or an authorized partner changes formulation, dosage form, or device
Stand-alone BLA	New sponsor develops a distinct biological product
Biosimilar BLA	Sponsor seeks approval based on analytical, pharmacologic, and clinical comparability
Combination-product pathway	Sponsor changes the delivery device or integrated administration system

A major formulation change could require clinical bridging, especially if it changes exposure, immunogenicity, infusion duration, injection-site tolerability, or device performance.

Which commercial opportunities are most attractive?

The strongest near-term opportunities are those that improve delivery without requiring a new active ingredient.

Priority opportunity ranking

Rank	Opportunity	Commercial rationale
1	Low-binding infusion set and pump cassette	Potentially lower regulatory risk and immediate dose-recovery value
2	Prefilled cartridge or ready-to-use system	Reduces preparation burden and handling errors
3	Room-temperature-stable formulation	Supports home use and lowers cold-chain costs
4	Higher-concentration formulation	Could shorten infusion time
5	Preservative-free multi-dose presentation	Reduces waste and pharmacy burden
6	New surfactant or stabilizer platform	Valuable if it improves agitation and thermal stability
7	Lyophilized formulation	Greater technical burden with uncertain convenience benefit

The largest commercial value would likely come from a product that combines formulation and device improvements. An excipient-only change may be difficult to monetize unless it produces a clear label advantage, such as longer room-temperature storage or reduced infusion time.

What revenue exposure does Empaveli create for Apellis and partners?

Empaveli is commercially important because it addresses rare diseases with high treatment intensity and chronic use. Its value is tied to:

• Twice-weekly administration for many PNH patients
• Long-term treatment duration
• Specialty-pharmacy distribution
• Home-infusion potential
• Expansion into C3G
• Complement-system competition from ravulizumab, eculizumab, iptacopan, danicopan, and other agents

The commercial risk is concentrated in administration burden, competition within complement inhibition, payer controls, and the emergence of biosimilar or follow-on pegcetacoplan products after regulatory and patent barriers weaken.

An improved formulation could protect revenue by increasing adherence and making switching less attractive. For suppliers, the most defensible opportunity is an integrated product with proprietary material compatibility, validated device performance, and formulation-specific stability data.

How does Empaveli compare with competing complement therapies?

Product	Target	Administration profile	Excipient opportunity
Empaveli	C3	Subcutaneous infusion, commonly twice weekly	High potential for concentration, device, and stability improvements
Soliris	C5	Intravenous infusion	Less direct subcutaneous-device overlap
Ultomiris	C5	Intravenous or subcutaneous presentations depending on indication	Competes on dosing interval and convenience
Fabhalta	Factor B	Oral capsule	Limited injectable-excipient relevance
Voydeya	Factor D	Oral tablet	Limited injectable-excipient relevance

Empaveli’s formulation opportunity is larger than for oral competitors because its administration system remains a visible part of the treatment burden. Its competitive position depends on whether subcutaneous delivery can become more convenient than intravenous C5 inhibition while maintaining reliable complement control.

Key Takeaways

• Empaveli is a preservative-free, aqueous pegcetacoplan formulation containing sodium chloride, acetic acid, sodium hydroxide, and water for injection.
• The central technical challenges are aggregation, adsorption, viscosity, container compatibility, and room-temperature stability.
• The best commercial opportunities are low-binding delivery systems, prefilled cartridges, pump cassettes, higher-concentration formulations, and preservative-free multi-dose systems.
• Empaveli is a biologic, so conventional Orange Book and Paragraph IV analysis does not apply in the same manner as for an NDA-approved small molecule.
• The principal U.S. reference-product exclusivity date is approximately May 14, 2033, based on the 12-year biologic exclusivity framework.
• The initial PNH orphan-drug exclusivity period is approximately through May 2028.
• Composition and manufacturing patents are likely more strategically important than conventional excipient patents.
• A differentiated formulation must deliver a label-level benefit, especially shorter infusion time, lower storage burden, or reduced preparation complexity.

FAQs

Can Empaveli be reformulated with a preservative?

Yes, but a preservative would require new safety, sterility, container-compatibility, and local-tolerability data. A preservative-free multi-dose device is likely a cleaner commercial strategy.

Could Empaveli be converted into an autoinjector?

A conventional autoinjector would face a dose-volume problem because the marketed regimen uses a large amount of drug. A higher-concentration formulation or wearable infusion device is more technically plausible.

Is a biosimilar to pegcetacoplan technically feasible?

It is feasible in principle but challenging because pegcetacoplan is a PEG-peptide conjugate with complex molecular and functional characterization requirements. Analytical comparability and manufacturing control would be central.

Would a new surfactant create a new patent opportunity?

Yes. A surfactant system tied to defined concentration ranges, stability outcomes, container materials, or administration conditions could support formulation and use claims. Its enforceability would depend on claim scope and prior art.

What is the most valuable excipient innovation for Empaveli?

A formulation and device combination that enables higher concentration, shorter infusion, and improved room-temperature stability would likely have the greatest commercial value. A commodity buffer substitution alone would have limited differentiation.

References

1. U.S. Food and Drug Administration. (2024). Empaveli (pegcetacoplan) injection prescribing information. Apellis Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Empaveli approval and supplemental approval materials. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Public Search. https://patentcenter.uspto.gov/

5. Biologics Price Competition and Innovation Act, 42 U.S.C. § 262(k)(7).

6. Orphan Drug Act, 21 U.S.C. § 360cc.